Loading patent…
AssigneeJuvena Therapeutics, Inc.
InventorsHanadie Yousef, Jeremy O'Connell, Thach Mai, Rami Jaafar, Zhihua Li
Estimating the term…
Described herein are polypeptides comprising an FGF17, IGF2, or BMP? amino acid sequence and an amino acid sequence from a heterologous polypeptide useful for the treatment of soft-tissue and muscle diseases, disorders, and injuries. Also described herein are synergistic combinations of a Fibroblast Growth Factor Receptor agonist and a glycosaminoglycan, an Insulin-like Growth Factor 1 Receptor (IGF1R) agonist and a short chain fatty acid, and BMP receptor agonists and mTOR activators and/or glycosaminoglycans. Also described are methods of treating muscle and soft-tissue diseases comprising administering the polypeptides and/or synergistic compositions.
A method of treating a muscle or soft-tissue disorder or condition in an individual comprising administering to the individual a therapeutically effective amount of a polypeptide comprising an Insulin-like growth factor (IGF) receptor ligand amino acid sequence and a heterologous polypeptide amino acid sequence, wherein the heterologous polypeptide amino acid sequence increases the stability or biological function of the IGF receptor ligand amino acid sequence.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
The method of claim 17, wherein the heterologous polypeptide amino acid sequence comprises a fragment of an immunoglobulin molecule and wherein the fragment of the immunoglobulin molecule comprises the hinge domain of an IgG, the CH2 domain of an IgG, the CH3 domain of an IgG, or any combination thereof.
The method of claim 18, wherein the fragment of the immunoglobulin molecule comprises one or more mutations that reduce the effector function of the fragment of the immunoglobulin molecule.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.